Piper Jaffray Companies started coverage on shares of Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) in a report released on Monday, MarketBeat.com reports. The firm issued an overweight rating and a $14.00 price objective on the biopharmaceutical company’s stock.

Several other equities research analysts have also recently commented on TTPH. BMO Capital Markets reaffirmed a buy rating and issued a $12.00 target price on shares of Tetraphase Pharmaceuticals in a research report on Friday, May 5th. Zacks Investment Research cut shares of Tetraphase Pharmaceuticals from a hold rating to a sell rating in a research report on Wednesday, May 10th. HC Wainwright initiated coverage on shares of Tetraphase Pharmaceuticals in a research report on Tuesday, July 11th. They issued a buy rating and a $15.00 target price for the company. Stifel Nicolaus raised shares of Tetraphase Pharmaceuticals from a hold rating to a buy rating and raised their target price for the stock from $8.00 to $15.00 in a research report on Wednesday, July 26th. Finally, Needham & Company LLC reissued a hold rating on shares of Tetraphase Pharmaceuticals in a research report on Thursday, July 27th. Four research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Tetraphase Pharmaceuticals has a consensus rating of Buy and an average price target of $11.21.

Shares of Tetraphase Pharmaceuticals (NASDAQ:TTPH) opened at 6.91 on Monday. The company’s market cap is $352.78 million. Tetraphase Pharmaceuticals has a 52-week low of $3.11 and a 52-week high of $9.93. The company has a 50 day moving average of $6.56 and a 200-day moving average of $7.09.

Tetraphase Pharmaceuticals (NASDAQ:TTPH) last posted its earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($0.83) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.76) by $0.07. Tetraphase Pharmaceuticals had a negative return on equity of 79.79% and a negative net margin of 2,092.20%. The company had revenue of $1.59 million during the quarter, compared to analysts’ expectations of $1.54 million. During the same period in the prior year, the business posted ($0.47) earnings per share. The company’s revenue for the quarter was up 28.2% on a year-over-year basis. Analysts forecast that Tetraphase Pharmaceuticals will post ($2.54) EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This news story was posted by Watch List News and is owned by of Watch List News. If you are reading this news story on another domain, it was illegally copied and reposted in violation of US & international trademark and copyright law. The legal version of this news story can be accessed at https://www.watchlistnews.com/tetraphase-pharmaceuticals-inc-ttph-research-coverage-started-at-piper-jaffray-companies/1532759.html.

In related news, insider Jacques Dumas sold 7,155 shares of Tetraphase Pharmaceuticals stock in a transaction dated Thursday, August 17th. The shares were sold at an average price of $5.86, for a total transaction of $41,928.30. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 5.50% of the company’s stock.

A number of hedge funds have recently added to or reduced their stakes in the stock. UBS Group AG raised its stake in Tetraphase Pharmaceuticals by 2.3% in the first quarter. UBS Group AG now owns 17,269 shares of the biopharmaceutical company’s stock worth $159,000 after buying an additional 387 shares in the last quarter. Schwab Charles Investment Management Inc. raised its stake in Tetraphase Pharmaceuticals by 0.7% in the second quarter. Schwab Charles Investment Management Inc. now owns 129,681 shares of the biopharmaceutical company’s stock worth $925,000 after buying an additional 874 shares in the last quarter. Teza Capital Management LLC raised its stake in Tetraphase Pharmaceuticals by 8.9% in the first quarter. Teza Capital Management LLC now owns 15,650 shares of the biopharmaceutical company’s stock worth $144,000 after buying an additional 1,281 shares in the last quarter. American International Group Inc. raised its stake in Tetraphase Pharmaceuticals by 7.1% in the first quarter. American International Group Inc. now owns 22,390 shares of the biopharmaceutical company’s stock worth $206,000 after buying an additional 1,486 shares in the last quarter. Finally, Citadel Advisors LLC raised its stake in Tetraphase Pharmaceuticals by 18.6% in the first quarter. Citadel Advisors LLC now owns 15,924 shares of the biopharmaceutical company’s stock worth $146,000 after buying an additional 2,496 shares in the last quarter. Institutional investors and hedge funds own 41.73% of the company’s stock.

Tetraphase Pharmaceuticals Company Profile

Tetraphase Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant gram-negative infections.

Analyst Recommendations for Tetraphase Pharmaceuticals (NASDAQ:TTPH)

Receive News & Ratings for Tetraphase Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.